NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)

NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies (TTI-622-01)

ClinicalTrials.gov Identifier: NCT03530683

Sponsor

Trillium Therapeutics Inc.

Multicenter, open-label, phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in subjects with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma.

Multiple Locations

International Study

---

ClinicalTrials.gov Identifier: NCT02899052

Official Title: A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma

First Posted : May 21, 2018

https://clinicaltrials.gov/ct2/show/NCT03530683

---

PF-07901801 (TTI-622)

CD47-SIRPa Fusion Protein

TTI-622

SIRPa-IgG4-Fc Fusion Protein TTI-622 (Code C150756)

SIRPa-IgG4 Fc

SIRPa-IgG4 Fc TTI-622

SIRPa-IgG4-Fc Fusion Protein TTI-622

TTI 622

TTI-622

TTI622

---

Drug: TTI-622

Drug: Azacitidine

Drug: Venetoclax

Drug: Carfilzomib

Drug: Dexamethasone

Drug: anti-CD20 Targeting agent

---

3560 CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Program: Oral and Poster Abstracts Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III Hematology Disease Topics & Pathways: Clinical Trials, Biological, Lymphomas, Clinical Research, B Cell Lymphoma, T Cell Lymphoma, Diseases, Indolent Lymphoma, Aggressive Lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies Monday, December 13, 2021, 6:00 PM-8:00 PM

Paper: CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study (confex.com)

---

Locations

United States, California

United States, Colorado

United States, District of Columbia

United States, Florida

United States, Georgia

United States, Kentucky

United States, Michigan

United States, New York

United States, Ohio

United States, Tennessee

United States, Texas

United States, Washington

---

Pfizer Completes Acquisition of Trillium Therapeutics

Learn more